Posted by Michael Wonder on 17 Aug 2022
UK will not buy Evusheld owing to “insufficient data” on protection, Government says
15 August 2022 - The UK Government has said that it will not procure the COVID-19 drug Evusheld—a combination of two long acting antibodies, tixagevimab and cilgavimab—because of “insufficient data” on the duration of protection it provides against omicron and its subvariants.
The government said that the decision was based on independent clinical advice from Rapid C-19—a multi-agency initiative including NHS England, the Medicines and Healthcare Products Regulatory Agency, the National Institute for Health Research, and the National Institute for Health and Care Excellence (NICE), as well as other health bodies from Scotland, Wales, and Northern Ireland.
